Showing results (281-290 of 293) with videos related to
Sort By:
Pageof 30
ACS Chemical Neuroscience|January 26, 2026
Discovery of 7-(Pyridin-3-yl)thieno[3,2-b]pyridine-5-carboxamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Scott H Henderson, Anna E Ringuette, David L Whomble, et al.ACS Medicinal Chemistry Letters|December 18, 2024
Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Elizabeth S Childress, Rory A Capstick, Katherine E Crocker, et al.Journal of Medicinal Chemistry|December 12, 2024
Discovery of VU6024578/BI02982816: An mGlu1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition ModelsCarson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of Thieno[3,2-b]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Katherine E Crocker, Scott H Henderson, Rory A Capstick, et al.Neuro-Oncology Pediatrics|March 27, 2026
Targeting the p53 pathway to treat atypical teratoid rhabdoid tumorsAlaa Refaat, Hyekyung P Cho, Justin S Williams, et al.Journal of Medicinal Chemistry|April 13, 2022
Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M5 Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use DisorderAaron T Garrison, Douglas L Orsi, Rory A Capstick, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 23, 2012
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsGregory J Digby, Meredith J Noetzel, Michael Bubser, et al.ACS Chemical Neuroscience|December 11, 2024
Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsMichael S Poslunsey, Michael R Wood, Changho Han, et al.ACS Chemical Neuroscience|June 6, 2026
Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu3 Positive Allosteric Modulator (PAM) with Efficacy in a Preclinical Cognition ModelCaleb A Jones, Renn A Duncan, Kristen M Gilliland, et al.Pageof 30